Skip to content
Open access

Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety

Oct 2026 · Journal of human immunity · Vol 3 · 0 citations · 37 references
Medicine

Abstract

Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. This publication demonstrates the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment, illustrating a positive tolerability profile and sustained disease burden reduction.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.